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Effects of drug resistance mutations L100I and V106A on the
binding of pyrrolobenzoxazepinone nonnucleoside inhibitors to
the human immunodeficiency virus type 1 reverse transcriptase
catalytic complex
Abstract
We have previously described a novel class of nonnucleoside reverse transcriptase (RT) inhibitors, the
pyrrolobenzoxazepinone (PBO) and the pyridopyrrolooxazepinone (PPO) derivatives, which were
effective inhibitors of human immunodeficiency virus type 1 (HIV-1) RT, either wild type or carrying
known drug resistance mutations (G. Campiani et al., J. Med. Chem. 42:4462-4470, 1999). The lead
compound of the PPO class, (R)-(-)-PPO464, was shown to selectively target the ternary complex
formed by the viral RT with its substrates nucleic acid and nucleotide (G. Maga et al., J. Biol. Chem.
276:44653-44662, 2001). In order to better understand the structural basis for this selectivity, we
exploited some PBO analogs characterized by various substituents at C-3 and by different inhibition
potencies and drug resistance profiles, and we studied their interaction with HIV-1 RT wild type or
carrying the drug resistance mutations L100I and V106A. Our kinetic and thermodynamic analyses
showed that the formation of the complex between the enzyme and the nucleotide increased the
inhibition potency of the compound PBO354 and shifted the free energy (energy of activation,
DeltaG(#)) for inhibitor binding toward more negative values. The V106A mutation conferred resistance
to PBO 354 by increasing its dissociation rate from the enzyme, whereas the L100I mutation mainly
decreased the association rate. This latter mutation also caused a severe reduction in the catalytic
efficiency of the RT. These results provide a correlation between the efficiency of nucleotide utilization
by RT and its resistance to PBO inhibition.
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We have previously described a novel class of nonnucleoside reverse transcriptase (RT) inhibitors, the
pyrrolobenzoxazepinone (PBO) and the pyridopyrrolooxazepinone (PPO) derivatives, which were effective
inhibitors of human immunodeficiency virus type 1 (HIV-1) RT, either wild type or carrying known drug
resistance mutations (G. Campiani et al., J. Med. Chem. 42:4462–4470, 1999). The lead compound of the PPO
class, (R)-()-PPO464, was shown to selectively target the ternary complex formed by the viral RT with its
substrates nucleic acid and nucleotide (G. Maga et al., J. Biol. Chem. 276:44653–44662, 2001). In order to
better understand the structural basis for this selectivity, we exploited some PBO analogs characterized by
various substituents at C-3 and by different inhibition potencies and drug resistance profiles, and we studied
their interaction with HIV-1 RT wild type or carrying the drug resistance mutations L100I and V106A. Our
kinetic and thermodynamic analyses showed that the formation of the complex between the enzyme and the
nucleotide increased the inhibition potency of the compound PBO354 and shifted the free energy (energy of
activation, G#) for inhibitor binding toward more negative values. The V106A mutation conferred resistance
to PBO 354 by increasing its dissociation rate from the enzyme, whereas the L100I mutation mainly decreased
the association rate. This latter mutation also caused a severe reduction in the catalytic efficiency of the RT.
These results provide a correlation between the efficiency of nucleotide utilization by RT and its resistance to
PBO inhibition.
The virus-encoded human immunodeficiency virus type 1
(HIV-1) reverse transcriptase (RT) is a major target for anti-
viral chemotherapy (18, 20). Two classes of inhibitors are tar-
geted to the viral RT: nucleoside RT inhibitors (NRTIs) and
nonnucleoside RT inhibitors (NNRTIs) (9, 11, 28). The latter
compounds are highly specific for HIV-1 RT and bind to the
enzyme at an allosteric site close distinct from the catalytic site,
behaving as typical noncompetitive inhibitors with respect to
the different substrates of the polymerization reaction (12, 23).
The NNRTIs nevirapine, delavirdine, and the most recently
licensed, efavirenz, are currently used in clinical practice (8)
and are characterized by less-severe adverse effects than
NRTIs or protease inhibitors (PIs) (26). Combinations of
NNRTIs with NRTIs and PIs, have been shown to suppress
plasma HIV-1 load longer than monotherapy or dual therapy,
allowing CD4T cell increase, immune system function restora-
tion, and clinical improvement (22, 35). However, the occur-
rence of just a few single amino acid substitutions in the RT
gene can confer resistance to most of the NNRTIs (14, 26, 29).
Therefore, the development of novel NNRTIs with improved
pharmacological, pharmacokinetic, and drug resistance muta-
tion profiles is critical for a more successful application of
NNRTIs in combination therapy. We have previously de-
scribed a novel class of NNRTIs based on an oxazepinone
skeleton, namely, pyrrolobenzoxazepinone (PBO) and pyri-
dopyrrolooxazepinone (PPO) derivatives, which were effective
inhibitors of HIV-1 RT, either wild type or carrying known
drug resistance mutations. Compared to the reference com-
pound nevirapine, several of the synthesized PBOs and PPOs
displayed a higher inhibitory activity against wild-type RT and
clinically relevant mutant RTs containing the single amino acid
substitutions L100I, K103N, V106A, Y181I, and Y188L (7). In
addition, we have shown that the lead compound of this class,
(R)-()-PPO464, was selectively targeting the ternary complex
formed by the viral RT with its substrates nucleic acid and
nucleotide. It showed a significant synergy with the NRTI
zidovudine and a favorable pharmacokinetic profile in mice
and rats, either alone or during coadministration with the
HIV-1 PI ritonavir (25). The results of the biological and
pharmacokinetic experiments suggest a potential clinical utility
of PBO and PPO analogs in combination with NRTIs against
strains of HIV-1 bearing mutations that confer resistance to
known NNRTIs. Due to the potential interest of PBOs as
novel NNRTIs, we sought to further investigate their mecha-
nism of action. For this purpose, we selected some PBO ana-
* Corresponding author. Mailing address: Istituto di Genetica Mole-
colare IGM-CNR, Consiglio Nazionale delle Ricerche, via Abbiate-
grasso 205, 27100 Pavia, Italy. Phone: 39-0382-546355. Fax: 39-0382-
422286. E-mail: maga@igm.cnr.it.
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logs (Fig. 1) with different inhibition potencies and drug resis-
tance profiles. In particular, we selected PBO354 because,
uniquely among the PBO derivatives originally developed,
showed significant reduced activity toward HIV-1 RT carrying
the L100 I and V106A mutations, and we compared it to the
closely related compounds NF269 and NF355, which, on the
other hand, had similar potencies against both mutants with
respect to the wild-type RT (7). Remarkably, PBO354 proved
also to be among the less-toxic compounds of the PBO class on
a variety of cell lines (7). We then studied the interaction of
these compounds with HIV-1 RT wild type or carrying the
drug resistance mutations L100I and V106A.
MATERIALS AND METHODS
Inhibitors. The PBO derivatives shown in Fig. 1 were synthesized as previously
described (7). Azidothymidine triphosphate (AZTTP) was obtained from Am-
ersham Biosciences.
Nucleic acid substrates. The homopolymers poly(rA) or poly(dA) (Amersham
Biosciences) were mixed at weight ratios in nucleotides of 10:1 to the oligomer
oligo(dT)12-18 (Amersham Biosciences) in 20 mM Tris-HCl (pH 8.0) containing
20 mM KCl and 1 mM EDTA, heated at 65°C for 5 min, and then slowly cooled
at room temperature. Calf thymus-activated DNA was prepared as described
previously (37).
Expression and purification of recombinant HIV-1 RT forms. The coexpres-
sion vectors pUC12N/p66(His)/p51 with the wild-type HIV-1 RT p66/p51 or the
point mutants L100Ip66/p51 and V106Ap66/p51 (6) were kindly provided by
S. H. Hughes (NCI-Frederick Cancer Research and Development Center) and
purified in two steps as described previously (24). Recombinant RT was purified
to 95% purity and had poly(rA)/oligo(dT) specific activities (see below) of
75,670 U/mg for RT wild type, 56,690 U/mg for RT L100I, and 62,760 U/mg for
RT V106A; 1 U of DNA polymerase activity corresponds to the incorporation of
1 nmol of deoxynucleotide monophosphate (dNMP) into acid-precipitable ma-
terial in 60 min at 37°C. The identity of the introduced mutations was confirmed
by sequencing (6).
HIV-1 DNA polymerase activity assay. RNA- or DNA-dependent DNA poly-
merase activity was assayed as follows: a final volume of 25 l contained buffer
A (50 mM Tris-HCl [pH 7.5], 1 mM dithiothreitol, 0.2 mg of bovine serum
albumin/ml, 4% glycerol), 10 mM MgCl2, 0.5 g of either poly(rA)/oligo(dT)1:10
or poly(dA)/oligo(dT)1:10 (0.3 M 3-OH ends), [3H]dTTP (1 Ci/mmol) as in-
dicated in the figure legends, and 2 to 4 nM RT. Reactions were incubated at
37°C for the indicated times. When activated DNA was used, [3H]deoxynucleo-
side triphosphates (dNTPs; 4 Ci/mmol) were added in place of dTTP, in the
presence of 0.04 mg of the DNA template/ml. Then, 20 l-aliquots were spotted
onto glass fiber filters (GF/C), which were immediately immersed in 5% ice-cold
trichloroacetic acid. Filters were washed twice in 5% ice-cold trichloroacetic acid
and once in ethanol for 5 min and then dried, and acid-precipitable radioactivity
was quantitated by scintillation counting.
Inhibition assays. Reactions were performed under the conditions described
for the HIV-1 RT RNA- or DNA-dependent DNA polymerase activity assay.
Incorporation of radioactive dTTP into poly(rA)/oligo(dT) or poly(dA)/oli-
go(dT) at different concentrations of dTTP was monitored in the presence of
increasing amounts of inhibitor as indicated in the figure legends.
Kinetics of inhibitor binding. HIV-1 RT (20 to 40 nM) was incubated 2 min
at 37°C in a final volume of 4 l in the presence of buffer A, 10 mM MgCl2, 100
nM 3-OH ends, and 10 M unlabeled dTTP (for the formation of the RT/TP/
dNTP complex). The inhibitor to be tested was then added to a final volume of
5 l at a concentration at which the [EI]/[E0] was (1  1/[1  [I]/Ki)]  0.9. Then,
145 l of a mix containing buffer A, 10 mM MgCl2, and 10 M [3H]dTTP (5
Ci/mmol) were added at different time points. After an additional 10 min of
incubation at 37°C, 50-l aliquots were spotted on GF/C filters, and the acid-
precipitable radioactivity was measured as described for the HIV-1 RT RNA-
dependent DNA polymerase activity assay. The quantity (vt/v0) representing the
normalized difference between the amounts of dTTP incorporated at the zero
time point and at the different time points was then plotted against time.
Kinetic parameter calculation. All values were calculated by non-least-squares
computer fitting of the experimental data to the appropriate rate equations. Km
and kcat values were calculated according to the Michaelis-Menten equation by
analyzing the variation of the initial velocities of the reaction in dependence on
the substrate concentration. Time-dependent incorporation of radioactive dTTP
into poly(rA)/oligo(dT) at different substrate concentrations was monitored by
removing 20-l aliquots at the 2-, 4-, 6-, and 12-min time points. The initial
velocities of the reaction, determined by linear regression analysis of the data,
were then plotted against the corresponding substrate concentrations.
Kapp values for the ternary complex were calculated according to the equation
for noncompetitive inhibition:
v Vm/Km/S	 1 I/Kapp	 (1)
The true equilibrium dissociation constant (Ki) was calculated from the variation
of Kapp as a function of the dTTP concentrations according to the equation:
Kapp 1 Km/S	Ki (2)
The apparent binding rate (kapp) values were determined by fitting the experi-
mental data to the single-exponential equation:
vt/v0	 ekappt (3)
where t is time. If [E]0 is the input enzyme concentration, [E]t is the enzyme
available for the reaction at time t, and [E:I]t is the enzyme bound to the inhibitor
at time t, it follows that [E]t 
 [E]0  [E:I]t. Since v0 
 kcat[E]0 and vt 
 kcat[E]t,
then vt/v0 
 1  [E:I]t/[E]0. Thus, the vt/v0 value is proportional to the fraction
of enzyme bound to the inhibitor.
The true association (kon) and dissociation (koff) rates were calculated from
the relationships:
kon kapp/I Ki	 and kof f  konKi
For the thermodynamic parameters calculations, H# and S# values for inhib-
itor binding were determined according to the van’t Hoff equation:
ln 1/Kapp	H#RT S#/R (4)
where R is the gas constant and T the absolute temperature (in Kelvins).
G# (energy of activation) was calculated from the equation:
G# H# TS#
The variation of G# as a function of the dTTP concentration was analyzed
according to the equation:
G# RTln[(1 Km/[S])Ki] (5)
FIG. 1. Structures of the PBO analogs used in the present study.
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The thermodynamic parameters for dTTP incorporation were calculated accord-
ing to the Eyring equation:
ln(kcat/T)H/T ln(kb/h) S/R (6)
where kb is Boltzmann’s constant, h is Planck’s constant, R is the gas constant,
and T is the absolute temperature (Kelvin).
The buffering system used (Tris-HCl [pH 7.]) is sensitive to the temperature.
However, in the range of temperatures used for the reactions, the variation was
comprised from pH 7.6 to 7.2, which corresponds to the 90% activity pH range
of HIV-1 RT.
RESULTS
Inhibition of HIV-1 RT by the PBO class of inhibitors is
dependent on substrate binding by the enzyme. We have pre-
viously shown that the NNRTI (R)-()-PPO464 specifically
targets the catalytically competent ternary complex of RT with
its nucleic acid and nucleotide substrates (25). As a conse-
quence, the potency of inhibition of (R)-()-PPO464 was
shown to increase as the concentration of the substrates was
increased. In order to verify whether this property was com-
mon to the PBO class of antiviral agents, wild-type HIV-1 RT
was challenged with the inhibitors PBO269, PBO354, and
PBO355 (shown in Fig. 1). According to the ordered mecha-
nism of the polymerization reaction, whereby template-primer
(TP) binds first, followed by the addition of dNTP, the HIV-1
RT can be present in three different catalytic forms: as a free
enzyme, in a binary complex with the TP and in a ternary
complex with T/P and dNTP (21). Thus, when the TP substrate
was held constant at a saturating concentration and the depen-
dence of the inhibition for various concentrations of dNTPs
was analyzed at the steady state, all of the input RT was in the
form of the RT-TP binary complex, and only two forms of the
enzyme (the binary complex and the ternary complex with
dNTP) could react with the inhibitor. Similarly, when the
dNTP concentration was kept constant at saturating levels and
the dependence of the inhibition was analyzed at various TP
concentrations, RT was present either as a free enzyme or in
the ternary complex with TP and dNTP. Thus, in both cases
simple steady-state kinetic analysis could be used for the de-
termination of the equilibrium dissociation constants of the
different enzyme-inhibitor complexes. When wild-type HIV-1
RT was challenged with the compound PBO354 in the pres-
ence of a saturating amount of RNA/DNA substrate poly(rA)/
oligo(dT) and in the presence of increasing concentrations of
the nucleotide substrate TTP the observed inhibition was of
the noncompetitive type (Fig. 2A). Similar results were ob-
tained when wild-type RT was challenged with different con-
centrations of PBO354 in the presence of increasing concen-
tration of the nucleic acid substrate [RNA/DNA substrate
poly(rA)/oligo(dT)] and saturating amounts of the nucleotide
dTTP (Fig. 2B). By using this approach, the apparent inhibi-
tion constants (Kapp) for all of the different inhibitors were
then determined, and their variation in dependence of the
nucleotide substrate concentrations is shown in Fig. 2C. All of
the inhibitors tested showed an increase in potency (reduction
of Kapp values), which was dependent on the TTP concentra-
tions. From these data it was possible to calculate the true
inhibition constant (Ki) for each inhibitor. The derived values
are listed in Table 1. The compound PBO354, bearing a fluo-
rine atom at position 3 of the pendant phenyl ring, showed the
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FIG. 2. All of the datum points represent the mean values of three independent experiments. Error bars indicate the standard deviations.
(A) HIV-1 RT wild type was tested on poly(rA)/oligo(dT) under the conditions described in Materials and Methods in the presence of 0.2 M
(3-OH ends) of poly(rA)/oligo(dT) at different fixed concentrations of dTTP (1, 2.5, 5, and 10 M) and increasing amounts of the inhibitor
PBO354 (0.25, 1, 5, and 15 M). The data were plotted according to the Lineweaver-Burk method. (B) HIV-1 RT wild type was tested on
poly(rA)/oligo(dT) under the conditions described in Materials and Methods in the presence of 50 M dTTP with different fixed concentrations
of poly(rA)/oligo(dT) (0.2, 0.08, 0.04, 0.02, and 0.008 M) and increasing amounts of the inhibitor PBO354 (0.25, 1, 5, and 15 M). The data were
plotted according to the Lineweaver-Burk method. (C) HIV-1 RT wild type was tested on poly(rA)/oligo(dT) in the presence of the different PBO
derivatives under the conditions described in Materials and Methods in the presence of different fixed concentrations of dTTP (0.2, 1, 2, 5, and
10 M) and increasing concentrations of the inhibitors (0.1, 0.25, 1, 5, 25, and 75 M). The Kapp values for the different inhibitors at each substrate
concentration were calculated from equation 1 as described in Materials and Methods. The variation of the Kapp values in dependence of the dTTP
concentrations was analyzed according to equation 2 to calculate the true Ki values.
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greatest potency of inhibition (Table 1), as well as the highest
increase in affinity for RT, dependent on the TTP substrate
(Fig. 2C). Thus, it was selected for further characterization.
HIV-1 RT drug resistance mutations V106A and L100I dif-
ferentially affect enzyme sensitivity to the inhibitor PBO354.
First, the apparent inhibition constants (Kapp) of PBO354 for
the L100I and V106A enzymes were determined in the pres-
ence of increasing concentration of the nucleotide substrate
TTP. As shown in Fig. 3A, in the case of the mutant V106A,
PBO354 showed an increase in potency of inhibition (i.e., a
decrease in Kapp values) that was comparable to the one ob-
served with wild-type RT, even if the absolute Kapp values were
higher for V106A due to the drug resistance induced by the
mutation. Interestingly, with the L100I mutant, there was no
FIG. 3. All of the datum points represent the mean values of three independent experiments. Error bars indicate the standard deviations.
(A) HIV-1 RT wild type and the L100I and V106A mutants were tested on poly(rA)/oligo(dT) under the conditions described in Materials and
Methods, with different fixed concentrations of dTTP (0.2, 1, 2, 5, and 10 M) and increasing concentrations of the inhibitors (0.1, 0.25, 1, 5, 25,
and 75 M). The Kapp values for the different inhibitors at each substrate concentration were calculated from equation 1 as described in Materials
and Methods. The variation of the Kapp values was plotted in dependence of the dTTP concentrations and analyzed according to equation 2 to
calculate the true Ki values. (B) Determination of the binding rate of PBO354 to HIV-1 RT wild type and mutants. Reactions were carried out
as described in Materials and Methods. The data were fitted to a simple exponential equation to derive the apparent binding rate Kapp, which was
used to estimate the kon and koff values (see Materials and Methods). (C) HIV-1 RT wild type was tested on poly(rA)/oligo(dT) under the
conditions described in Materials and Methods, with different fixed concentrations of dTTP (0.2, 1, 2, 5, and 10 M) and increasing concentrations
of the PBO354 inhibitor (0.1, 0.25, 1, 5, 25, and 75 M). Reactions were carried out at different temperatures (24, 26, 30, 35, and 37°C). The Kapp
values for PBO354 at each substrate concentration were calculated as described in Materials and Methods and plotted with respect to different
reaction temperatures. Calculation of the thermodynamic parameters was performed by using equation 4. (D) Variation of the G# for complex
formation between the PBO354 inhibitor and HIV-1 RT wild type or carrying the L100I and V106A mutations. Experiments were carried out as
described in panel C with RT wild type or with the L100I and V106A mutants. The corresponding G# values were determined as explained in
Materials and Methods and plotted in dependence of the dTTP concentrations. The data were fitted to equation 5.
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significant variation of the Kapp values of PBO354 depending
on the TTP substrate concentrations. We have also observed
this effect with the other PBO derivatives shown in Fig. 1 (data
not shown), indicating that the lack of increase of the inhibi-
tion potency in dependence of the substrate concentration was
not specific for the particular compound tested but rather was
an intrinsic property of the L100I mutant enzyme.
Resistance to PBO354 is due to changes in the association
and dissociation rates of the inhibitor for the HIV-1 RT mu-
tants. Next, the kinetics of PBO354 binding to wild-type RT
and the L100I and V106A mutants were investigated. A pre-
formed ternary complex of RT with its substrates was chal-
lenged for increasing times with a saturating concentration of
the inhibitor. The residual activity of RT was defined as the
ratio of the reaction velocity at time t (vt) after incubation with
the inhibitor and the velocity in the absence of the inhibitor
(v0) and was measured as described in Materials and Methods.
The variation of vt/v0 with time is shown in Fig. 3B. The data
were fitted to a simple exponential equation to calculate the
apparent rate of inhibitor association (kapp). This value was
used to calculate the true association (kon) and dissociation
(koff) rates, which are listed in Table 1. The inhibitor showed
similar kon values for the wild-type and V106A enzymes but
dissociated 2.5-fold faster (higher koff rate) from the latter. On
the other hand, respectively, a 2.5-fold-slower association rate
and a 7-fold-faster dissociation rate of the inhibitor were mea-
sured for the L100I mutant with respect to wild-type RT.
These data clearly indicated a difference in the mechanism of
resistance to PBO354 between the V106A and the L100I mu-
tants.
Effects of drug resistance mutations L100I and V106A on
the thermodynamics of PBO354 binding to HIV-1 RT. The
effects of the reaction temperature on the binding of the
PBO354 inhibitor to HIV-1 RT were investigated for the wild-
type enzyme and the L100I and V106A mutants. The Kapp
values for inhibition were determined as described above (see
Materials and Methods) in the presence of increasing TTP
substrate concentrations and at different temperatures.
Through these measurements it was possible to calculate the
Kapp values for each temperature and for each substrate con-
centration, which were used to estimate the G#, H#, and
S# values for the inhibitor binding. As an example, the anal-
ysis performed for wild-type HIV-1 RT with PBO354 is shown
in Fig. 3C. The calculated values are listed in Table 1. As can
be seen, both the V106A and the L100I mutations increased
the activation enthalpy (H#) for inhibitor binding. However,
the more favorable entropic contribution (S#) for the V106A
mutant, with respect to L100I, determined a significant differ-
ence in the G# values between the two mutants. As a result,
binding of the inhibitor to the L100I enzyme was sixfold less
favored than to the V106A enzyme and 20-fold less favored
with respect to the wild-type enzyme. Next, we analyzed the
variation of the G# values with respect to the TTP concen-
tration. As shown in Fig. 3D, in the case of wild-type RT and
of the V106A mutant, increasing the nucleotide substrate con-
centrations yielded more negative G# values, thus rendering
the binding of the inhibitor thermodynamically favored. On the
other hand, no significant variations in the G# were observed
in the case of the L100I mutant. These results were in good
agreement with the observed dependence of the Kapp values
form the TTP concentration (Fig. 3A) and provide a thermo-
dynamic explanation for the increase in inhibition potency of
PBO354 in the case of the wild-type and V106A enzymes.
The mechanism of inhibition of HIV-1 RT by PBO354 is
similar for both RNA-dependent and DNA-dependent DNA
synthesis. HIV-1 RT can perform both RNA-dependent
(RDS) and DNA-dependent (DDS) DNA synthesis. The ex-
periments described above were performed under RDS con-
ditions, with the homopolymeric RNA/DNA hybrid template
poly(rA)/oligo(dT). However, it is known that the nature (ei-
ther RNA or DNA) of the template to be copied can influence
the sensitivity of RT to its inhibitors. For this reason, the
variations of the Kapp of PBO354 with respect to the TTP
concentration were measured under DDS conditions with the
homopolymeric DNA template poly(dA)/oligo(dT). As shown
in Fig. 4A, in the case of the wild-type enzyme the inhibitor
showed an increase in the affinity that was dependent on the
TTP concentration, similar to what was observed under RDS
conditions (Fig. 3A). In the case of the mutant V106A, the
enzyme showed lower sensitivity to PBO354 on this template
(i.e., higher Kapp values) with respect to the RDS conditions
(Fig. 3A). However, a similar increase in potency of inhibition
for PBO354 was observed in dependence of the TTP concen-
tration also for this mutant. Again, there was no increase in the
inhibition of the mutant L100I by PBO354 with respect to the
nucleotide substrate concentration. We wanted also to test
whether the homopolymeric versus heteropolymeric nature of
the template could affect the mechanism of inhibition of HIV-1
RT by PBO354. To do this, the RT wild type or the L100I and
V106A mutants were challenged with increasing concentra-
tions of the inhibitor on a heteropolymeric DNA template
(activated DNA, which is a genomic DNA treated with DNase
1 to create gaps [see Materials and Methods]). As shown in
Fig. 4C, the sensitivities of the different enzymes toward
PBO354 were decreased (higher Kapp values) with respect to
the homopolymeric DNA template (see Fig. 4A); however,
once again the Kapp values for RT inhibition decreased as the
dNTP concentration increased for wild-type RT and V106A
enzyme but not for the mutant L100I enzyme.
The L100I mutation confers resistance to PBO354 by de-
creasing the catalytic efficiency of HIV-1 RT. Since the L100I
mutation apparently abolished the observed dependence of the
inhibition potency by PBO354 from the nucleotide substrate
concentration, we wanted to investigate in more detail the
enzymological properties of this enzyme. Figure 4B shows the
variation of the reaction velocity for wild-type HIV-1 RT,
L100I, and V106A with respect to the TTP concentration un-
der both RDS and DDS conditions. In both cases, the L100I
mutant showed a lower catalytic efficiency with respect to wild-
type RT and the V106A mutant. The calculated Km, kcat, and
kcat/Km values for TTP utilization are listed in Table 2. In
general, the catalytic efficiency decreased from RDS to DDS
for all of the enzymes, an effect that has been previously ob-
served. However, under both RDS and DDS conditions, the
kcat and kcat/Km values for TTP were significantly lower for the
L100I mutant than for either wild-type RT or the V106A
mutant. In order to more precisely define this difference, sim-
ilar substrate titration experiments were performed at different
reaction temperatures, and the thermodynamic parameters for
TTP utilization were determined from the variations of the kcat
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FIG. 4. All of the datum points represent the mean values of three independent experiments. Error bars are indicated as standard deviations.
(A) HIV-1 RT wild type and the L100I and V106A mutants were tested on poly(dA)/oligo(dT) under the conditions described in Materials and
Methods, with different fixed concentrations of dTTP (0.2, 1, 2, 5, and 10 M) and increasing concentrations of the PBO354 inhibitor (0.1, 0.25,
1, 5, 25, and 75 M). The Kapp values at each substrate concentration were calculated as described in Materials and Methods. The variation of the
Kapp values was plotted in dependence of the dTTP concentrations and analyzed according to equation 2 to calculate the true Ki values. (B) HIV-1
RT wild type and the L100I and V106A mutants were assayed on poly(rA)/oligo(dT) (RDS, upper panel) or poly(dA)/oligo(dT) (DDS, lower
panel) as described in Materials and Methods. The initial velocities of the reaction were derived from time course experiments (see Materials and
Methods) in the presence of increasing concentrations of dTTP (0.1, 0.2, 1, 2, 5, and 10 M for RDS and 0.2, 0.5, 1, 2, 5, 10, and 20 M for DDS).
The variation in the initial velocities of the reaction was then plotted with respect to the substrate concentrations. The data were fitted to the
Michaelis-Menten equation in the form, i.e., v 
 kcat[E]0/(1  Km/[dTTP]), to calculate the Km and kcat parameters. (C) HIV-1 RT wild type and
the L100I and V106A mutants were tested on activated DNA as described in Materials and Methods, with different fixed concentrations of the
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values. The estimated G#, H#, and S# values for the
reaction are listed in Table 2. HIV-1 wild-type RT and the
V106A enzymes showed similar values for the G# for the
reaction. Significantly, the overall reaction was less favored
(compare the G# values) for L100I than for the wild-type
enzyme.
The nonnucleoside inhibitor efavirenz shows a mechanism
of inhibition similar to that of PBO354. Efavirenz is a expand-
ed-spectrum NNRTI that is used in clinical practice. We have
previously shown that efavirenz has a higher affinity for the
ternary complex of RT and its DNA and dNTP substrates than
for either the binary RT-DNA complex or the free enzyme
(27). Thus, we have investigated the relationship of efavirenz
inhibition to the nucleotide substrate concentration. As shown
in Fig. 4D, the Kapp for efavirenz decreased as the nucleotide
concentration increased for wild-type RT and the V106A mu-
tant. Again, no influence of the nucleotide concentration was
found on the Kapp values for inhibition of L100I by efavirenz.
These data suggested that the preferential binding of efavirenz
to the ternary complex proceeds through a mechanism analo-
gous to the one observed for PBO354 and that the L100I
mutation affects this mechanism in a similar way for both
inhibitors.
The L100I mutation abolishes the specific targeting of the
ternary complex of HIV-1 RT and its substrates by the PBO
class of inhibitors. Finally, we examined the mechanism of
inhibition of the mutant L100I by the PBO269 and PBO354
inhibitors. The inhibition assays were performed as described
for the experiments shown in Fig. 2A and B, namely, keeping
one substrate constant at saturating levels and varying the
concentration of the other. In the case of wild-type RT,
PBO354 acted as an noncompetitive inhibitor (Fig. 2A and B).
In contrast, as shown in Fig. 5A and B, the inhibition of L100I
by PBO354 was noncompetitive with respect to both sub-
strates. Similar results were obtained with the inhibitor
PBO269 (Fig. 5C and D). According to the ordered mecha-
nism of the polymerization reaction, these data indicated that
the L100I mutation abolished the specific targeting of the
ternary RT/TP/dNTP complex by the PBO derivatives, which
now can bind to the enzyme independently from the substrates,
thus acting as a noncompetitive inhibitor. In conclusion, these
results indicated that the lack of increase of the inhibition
potency and the absence of a decrease (more negative values)
of the G# for inhibitor binding in dependence of the sub-
strate concentration observed with the L100I mutant corre-
lated with the impairment of PBO binding to the ternary com-
plex of RT and its substrates.
DISCUSSION
Previous observations indicated that the inhibition of HIV-1
RT by the NNRTI PPO464 was due to the specific binding of
this molecule to the ternary complex formed by RT, the tem-
plate primer, and the dNTP (25). In the present study we
extended the analysis to molecules belonging to a related class
of NNRTIs, the PBO derivatives, whose structures are shown
in Fig. 1. The observed increase in inhibition potencies for
these compounds with respect to the nucleotide substrate con-
centration, at saturating concentrations of the nucleic acid
substrate (Fig. 2C and Table 1) suggested a preference for the
ternary complex, as with PPO464. Comparison of the struc-
tures of the unliganded enzyme with those of the enzyme-DNA
and enzyme-DNA-dNTP complexes, showed differences in the
relative positions of the fingers and thumb subdomains, involv-
ing the structural elements surrounding the NNRTI binding
pocket (15, 16, 17, 19, 33). Thus, it is possible that local struc-
tural differences might facilitate the access of PBO inhibitors
to the binding site, partially explaining the observed mecha-
nism of inhibition. Previous observations have shown that the
carboxanilide derivatives bind with different affinities to the
various enzyme-substrate complexes in the RT reaction path-
way (13). Moreover, in a previous study we showed that the
extended-spectrum NNRTI efavirenz displayed preferential
affinity for either the binary or the ternary complex of RT with
TABLE 2. Kinetic and thermodynamic parameters for dTTP utilization by RT wild type and mutants
Parameter
Mean value (SD)a
RDS DDS
Wild type V106A L1001 Wild type V106A L1001
Km (M) 1 (2) 13 (1) 4.5 (0.5) 18 (2) 25 (2) 12 (1)
kcat (s
1) 0.48 (0.05) 0.5 (0.06) 0.04 (0.01) 0.18 (0.03) 0.2 (0.06) 0.016 (0.002)
kcat/Km (s
1 M1) 0.028 (0.003) 0.038 (0.004) 0.009 (0.001) 0.01 (0.001) 0.008 (0.001) 0.001 (0.0002)
H# (kcal mol1) 11 (1) 10 (1) 7 (0.7)
S# (cal mol1 K1) 40 (5) 35 (3) 23 (2)
G#(310)
b (kcal mol1) 1.4 (0.2) 0.85 (0.2) 0.13 (0.02)
a Values for the kinetic parameters represent the mean of three independent experiments.
b G#(310), energy of activation at T 
 310 K.
dNTPs (0.5, 1, 2, 5, and 10 M) and increasing concentrations of the PBO354 inhibitor (0.1, 0.25, 1, 5, 25, and 75 M). The Kapp values at each
substrate concentration were calculated as described in Materials and Methods. The variation in the Kapp values was plotted in dependence of the
dTTP concentrations and analyzed according to equation 2 to calculate the true Ki values. (D) HIV-1 RT wild type and the L100I and V106A
mutants were tested on poly(rA)/oligo(dT) under the conditions described in Materials and Methods, with different fixed concentrations of dTTP
(1.5, 2.5, 5, and 10 M) and increasing concentrations of the efavirenz inhibitor (0.1, 0.25, 1, 5, 25, and 75 M). The Kapp values at each substrate
concentration were calculated as described in Materials and Methods. The variation in the Kapp values was plotted with respect to the dTTP
concentrations and analyzed according to equation 2 to calculate the true Ki values.
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its substrates with respect to the unliganded enzyme (27).
Thus, it is conceivable that there is an induced fit mechanism
for the binding of some classes of NNRTIs that is triggered by
complex formation among RT and the nucleic acid and nucle-
otide substrates.
The inhibitor PBO354 showed an overall decreased potency
toward RT containing the drug resistance mutations L100I and
V106A, even though this was to a much lower extent than
narrow-spectrum NNRTIs such as nevirapine (Table 1) (see
also reference 7). Interestingly, PBO354 showed an increase in
inhibition potency with respect to the nucleotide substrate
concentration in the case of the V106A mutant but not with
the L100I (Fig. 3A). Investigation of the binding kinetics of the
inhibitors to these two mutants showed that the V106A muta-
tion induced resistance by increasing the koff rate of the inhib-
itor, whereas the L100I mutation affected both the kon and the
koff rates (Fig. 3B). These data collectively suggested that the
L100I mutation might alter the structure of the ternary com-
plex of RT with its substrates, interfering with the induced fit
mechanism of inhibition by the PBO analogs. This hypothesis
FIG. 5. All of the datum points represent the mean values of three independent experiments. Error bars are indicated as standard deviations.
(A) The HIV-1 RT L100I mutant was tested on poly(rA)/oligo(dT) under the conditions described in Materials and Methods in the presence of
0.2 M (3-OH ends) of poly(rA)/oligo(dT) at different fixed concentrations of dTTP (1, 2.5, 5, and 10 M) and with increasing concentrations
of the inhibitor PBO354 (1, 2.5, 7.5, and 15 M). The data were plotted according to the Lineweaver-Burk method. (B) HIV-1 RT L100I was tested
on poly(rA)/oligo(dT) under the conditions described in Materials and Methods in the presence of 50 M dTTP, with different fixed concentrations
of poly(rA)/oligo(dT) (0.04, 0.02, 0.01, and 0.004 M) and increasing concentrations of the inhibitor PBO354 (1, 2.5, 7.5, and 15 M). The data
were plotted according to the Lineweaver-Burk method. (C) Same as in panel A, but with the PBO269 inhibitor. (D) Same as in panel B, but with
the PBO269 inhibitor.
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is further supported by the observation that the L100I enzyme
showed a lower catalytic rate and nucleotide substrate utiliza-
tion efficiency than RT wild type and V106A (Fig. 4B and
Table 2) and that the PBO derivatives inhibited this mutant
with a noncompetitive mechanism (Fig. 5A and B). Thermo-
dynamic analysis of inhibitor binding showed that saturation of
the enzyme with the nucleotide substrate favored the reaction
(increase in negative G# values, Fig. 3D), only in the case of
RT wild type and V106A and not for the L100I mutant. Table
1 shows that the unfavorable binding was due mainly to an
increase in the enthalpy (H), which is not compensated for by
a correspondent variation in the entropic term. The impor-
tance in the balance between H and S in inhibitor binding
has been also shown in the case of HIV-1 RT PIs (30). The
decrease in potency of the PBO inhibitors, is therefore appar-
ently caused by the combination of both an increase in the
activation energy for complex formation (likely due to a steric
barrier induced by the L100I substitution) and a lack of en-
tropic compensation.
Specific RT mutations have variable effects on different in-
hibitors (5, 10, 29). The L100I single point mutation, for ex-
ample, has only a moderate effect on nevirapine but causes a
100-fold loss of activity for 9-Cl TIBO, a structurally different
NNRTI (4). Our results from direct binding studies (Table 1),
showed that the L100I mutation reduced the rate of the asso-
ciation (kon) of the PBO354 inhibitor to the enzyme, whereas
the V106A mutation increased its dissociation rate (koff). We
have previously shown that in the case of nevirapine, both
L100I and V106A mutations caused an increase in the koff rate
without significantly affecting the kon value (24). Thus, the
observed effect of the L100I mutation on PBO354 binding
seems to be specific for this class of compounds. Docking
models of PBO compounds into the RT NNRTI-binding site,
based on the structure of the RT-nevirapine complex, showed
that no hydrogen bonds involved the oxygens of the inhibitor
but that both the fused pyrrole and the pendant phenyl ring at
C-6 of the PBO structure were in close contact with the side
chains of Y181, V106, K103, K101, and L100 (7). L100I is an
isosteric replacement, with the isoleucine -methyl group
pointing directly toward a ring of each ligand and adjacent to
any group that is hydrogen bonded with K101. Thus, the L100I
mutation is likely to cause either a steric penalty and/or to
destabilize the hydrogen bonding to K101. In contrast, the
V106A mutations represent significant size reductions, which
diminish favorable hydrophobic contacts between the enzyme
and the inhibitors. Thus, it is conceivable to hypothesize that
the L100I substitution would act mainly by introducing a steric
barrier to PBO binding. This mechanism has been previously
proposed for structurally different NNRTIs based on molecu-
lar modeling simulations (36).
The observation that the L100I enzyme showed a lower
catalytic efficiency (Table 2) suggested a correlation between
the observed resistance of L100I to the PBO354 inhibitor and
the loss of catalytic efficiency for TTP utilization of the mu-
tated enzyme. It should be noted here that the exact nature of
the rate-limiting step (kcat) is not known, nor can it be deter-
mined under these experimental conditions. Thus, the ob-
served differences in G# values could also be due, in princi-
ple, to a change in the nature of the rate-limiting step of the
reaction. However, regardless of the identity of the slowest
step of the reaction, the analysis shown here clearly indicated
a difference in the thermodynamics of the nucleotide incorpo-
ration reaction among the different enzymes tested.
Given the particular nature of the mechanism of RT inhibi-
tion by the PBO class of NNRTIs, it might be hypothesized
that the L100I mutation specifically altered the geometry of the
active site of the enzyme. The RT enzyme undergoes to sub-
stantial structural rearrangements upon binding to its sub-
strates, nucleic acid and nucleotide. Gaussian network model-
ing of the collective motions of HIV-1 RT identified some
regions of the protein that appeared to act as molecular hinges
for the large-scale movements of the RT subdomains (3, 34).
One of these regions corresponded to the loop in the p66 palm
subdomain which contains the L100 residue. Thus, the L100I
substitution might interfere with this hinge function, perhaps
causing a sort of “molecular arthritis” to HIV-1 RT, impairing
the correct positioning of the catalytic triad formed by the
residues D110, D185, and D186 and reducing nucleotide in-
corporation.
In summary, our data provide further insights into the mech-
anism of inhibition of HIV-1 RT by the PBO class of com-
pounds, suggesting the possibility of designing novel molecules
with low toxicity and high potency to be used in combination
therapies as an alternative to the currently used efavirenz and
nevirapine. One observation stemming from the present study
is that PBO resistance induced by the L100I mutation was
achieved through a significant loss of catalytic efficiency of the
mutated enzyme. This implies that such a mutation will be
fixed in the viral population only in the presence of a strong
selective pressure. Indeed, viruses carrying the L100I mutation
in the RT gene are very frequently isolated in HIV-1-infected
patients treated with NNRTIs but are very rare in naive pa-
tients (2, 31). The V106A mutation is also very rare, and it has
been shown that the virus carrying this mutation displays a
significantly reduced fitness. This is apparently in contradiction
to our findings that the catalytic properties of the V106A RT
are similar to the wild-type enzyme (Table 2). However, it has
been recently shown that the replicative defect of the V106A
mutant viruses is likely due to an impairment of the RNase H
activity of the viral RT (1), thus explaining this apparent par-
adox.
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